Class summary at a glance.

Every drug in the Programmed Death Ligand-1 Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $49.7Mcombined across class
Total Rx claims: 4K985 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Durvalumab

Brand: IMFINZI · 4K Part D claims (CY24) · 931 beneficiaries · First FDA approval: 2017-05-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $46.2M

Class share

93%

of class CY24 spend

View profile →

Avelumab

Brand: BAVENCIO · 282 Part D claims (CY24) · 54 beneficiaries · First FDA approval: 2017-03-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $3.5M

Class share

of class CY24 spend

View profile →

Cosibelimab

Brand: UNLOXCYT · — Part D claims (CY24) · First FDA approval: 2025-12-08

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.